Paris - Delayed Quote EUR

Valerio Therapeutics Société anonyme (ALVIO.PA)

Compare
0.0790 +0.0030 (+3.95%)
At close: December 23 at 5:16:10 PM GMT+1

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Julien Miara CEO & Chairman -- -- 1983
Dr. Shefali Agarwal M.D., MPH President -- -- 1973
Ms. Joyce Carey Executive Director of Finance and Head of FP&A -- -- --
Ms. Robin Sutherland VP & Global Head of Human Resources -- -- --
Mr. Michel Forest Chief Pharmacist & Quality Assurance Director -- -- --
Ms. Huiping Jiang Senior Vice President of Regulatory Affairs & Quality Assurance -- -- --
Mr. Wael Jdey Ph.D. Head of Preclinical -- -- --
Dr. Donna Cabral-Lilly Ph.D. VP & Head of CMC -- -- --
Ms. Pam Slatcher Head of Global PV -- -- --

Valerio Therapeutics Société anonyme

49, boulevard du GEnEral Martial Valin
Paris, 75015
France
33 1 70 38 33 99 https://valeriotx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
38

Description

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France.

Corporate Governance

Valerio Therapeutics Société anonyme’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

September 30, 2024 at 8:40 PM UTC

Valerio Therapeutics Société anonyme Earnings Date

Recent Events

Related Tickers